Stabilizing and Transferring a Tablet Production Line
Pharmaceutical company with cross-site tablet production
Critical problems in the tablet production line led to budget escalation, production bottlenecks and frequent batch failures.
The challenge
The situation
Critical problems in the tablet production line led to a budget escalation and considerable production bottlenecks. The existing processes were inefficient and caused frequent batch failures and delays to the product launch.
Our approach
What we delivered
Optimized shift planning for the production line, to resolve the bottlenecks that were delaying the launch.
Upgrade of the tablet press in response to the frequent batch failures originating from the equipment itself.
Strategic hire to coordinate the line, so that the optimization has someone accountable for it beyond the project period.
The outcome
Results & impact
Four months to launch
Product launch achieved within four months.
5% batch failure rate
Reduced rate of batch failures in the production line.
EUR 25 million budget frame
Implementation within the defined budget frame.
In summary
The tablet production line is stabilized; the product launch was achieved within four months and within the set budget frame.
Related expertise
Production Transfer & Scale-Up →
Transfer strategy and gap analysis between donor and receiving site, scale-up under ICH Q8
Lean Manufacturing →
Systematic OEE measurement and changeover time reduction via SMED in a validated environment
CAPEX Planning & Qualification →
A User Requirement Specification with GMP requirements, FAT, SAT and qualification
Lean Six Sigma →
Value stream mapping and Six Sigma belt programs in regulated production
Similar projects
More on Pharma →Sources
- Entourage project experience (anonymized)
Your project
A comparable project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.us
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences



